Mevion develops and sells compact proton therapy systems, including the HYPERSCAN™ pencil beam scanning solution that uses the Adaptive Aperture™ proton MLC. The company positions HYPERSCAN as a breakthrough in proton therapy and already has clinical use at MedStar Georgetown University Hospital, with installations at an NCI‑Designated Cancer Center in the U.S. and the MAASTRO Clinic in the Netherlands. Mevion reports strong commercial interest in the United States and Europe and is negotiating additional units in Asia, with two additional centers in final design. The $150 million financing will be used to further distance Mevion’s technological leadership, expand manufacturing capacity to meet increased interest, and support expansion into emerging markets and the Asia Pacific region. The transaction also clears existing debt and optimizes the shareholder structure. The new and existing investor group collectively manages over $10 billion in assets, providing a long‑term capital base. Mevion Medical Systems is a leading provider of proton therapy systems whose flagship product is the MEVION S250, the only modular single‑room proton therapy system currently on the market. The MEVION S250 delivers targeted radiation therapy at a fraction of the size, operating costs and energy use of legacy systems, with a single‑room footprint of about 2,000 sq. ft. and high operational efficiency. Mevion has installed systems at Barnes‑Jewish Hospital, Ackerman Cancer Center, and Robert Wood Johnson University Hospital and achieved rapid patient ramp‑up (first 100 patients in 11 months; ACC reached 350 patients/year in under three months; RWJ treated its first patient less than four weeks after ACC). The company is privately held and based in Littleton, Massachusetts, with international offices in the United Kingdom and Japan. Mevion announced an investment agreement for up to $200 million to accelerate worldwide expansion and to increase manufacturing capacity and global service capability to support new installations in the U.S., China and internationally. Concurrent with the investment, Mevion and the lead investors will form a joint venture in China to produce, sell and service proton therapy systems for the Chinese market. Mevion Medical Systems develops and supplies the MEVION S250, a single-room proton therapy system designed to deliver precise radiation with a reduced size and lower implementation cost compared with legacy proton systems. The MEVION S250 preserves the clinical benefits of traditional proton therapy while offering improved reliability, efficient clinical workflow, and a footprint similar to modern X-ray radiation therapy devices. The system is FDA-cleared for clinical use and the first MEVION S250 is installed at the S. Lee Kling Center for Proton Therapy at Barnes Jewish Hospital/Washington University Medical Center, currently undergoing clinical acceptance and commissioning. Mevion reports five centers under installation and construction and more than a dozen centers under planning, positioning the company for wider deployment. The company says its technology makes proton therapy more accessible and practical for hospitals and patients, including pediatric and high‑risk cases. To support this expansion, Mevion has raised additional capital to accelerate deployment of the MEVION S250 in the U.S. and internationally. Mevion Medical Systems is the developer of the MEVION S250 Proton Therapy System, a compact proton beam radiation device powered by a TriNiobium Core designed to reduce cost, size and complexity compared with traditional proton systems. The company says the S250 preserves the treatment benefits of proton therapy while improving accessibility and practicality for wider clinical deployment. Mevion has delivered its first system and has two additional systems under installation. The MEVION S250 had not yet been cleared by the U.S. FDA for clinical use at the time of the announcement. The company announced a $45 million investment to accelerate manufacturing and worldwide deployment of the S250. Mevion was founded in 2004 and is headquartered in the Boston metropolitan area, with international offices in the United Kingdom and Japan.

Total raised

$450M

Funding rounds

5

Latest round

Equity

Latest activity

Jun 2018